The startup develops cancer medicines and treatments that expedite the clinical trial process, enabling faster access to therapies for patients. By streamlining drug development, the company increases the availability of effective cancer treatments, addressing the urgent need for timely interventions in oncology.
Funding
$151.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of new cancer treatments is a lengthy and complex process, often resulting in delays in making potentially life-saving therapies available to patients. Traditional clinical trial processes can be inefficient and costly, hindering the progress of promising drug candidates.
Solution
Ellipses Pharma is a drug development company focused on accelerating the clinical development of oncology medicines. The company employs an innovative drug development model that combines unbiased asset selection, de-risking, and continuous funding to minimize the time required to advance lead products through clinical trials. Ellipses Pharma leverages a Scientific Affairs Group comprised of oncology key opinion leaders to validate the science and clinical application of each asset. This approach aims to streamline the clinical trial process, enabling faster access to effective cancer treatments for patients in need.
Target Audience
The primary target audience includes oncology patients, healthcare professionals, and pharmaceutical companies seeking to expedite the development and availability of cancer treatments.
Features
- Focus on oncology-specific drug development
- Innovative drug development model combining unbiased asset selection and continuous funding
- Scientific Affairs Group comprised of key opinion leaders for independent validation
- Portfolio of small molecule and monoclonal antibody therapies
- Clinical-stage assets include EP0042 (dual FLT3 & Aurora kinase inhibitor), EP0062/vosilasarm (selective androgen receptor modulator), and EP0031 (selective RET inhibitor)
- EP0031/A400 granted Fast Track Designation by the FDA
- EP0042 received Orphan Drug Designation from the U.S. FDA